Fresenius Medical Care AG & Co. KGaA
New York Stock ExchangeRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Fresenius Medical Care AG & Co. KGaA, the world's leading provider of dialysis products and services, offers a comprehensive portfolio along the entire dialysis value chain, including dialysis machines such as the 2008T BlueStar and Liberty Select systems, dialyzers like Optiflux, reverse osmosis water purification systems, renal pharmaceuticals, therapeutic apheresis solutions, and related disposables and supplies; it operates approximately 3,700 dialysis clinics serving over 299,000 patients worldwide as of December 2024, with around 40 production sites across all continents and a dominant 38% market share in the US dialysis sector. Founded in 1996 through the merger of Fresenius AG's dialysis division and National Medical Care, the company maintains global headquarters in Bad Homburg vor der Höhe, Germany, North American headquarters in Waltham, Massachusetts, and regional hubs in Hong Kong for Asia-Pacific and Rio de Janeiro for Latin America; it focuses on chronic and acute kidney disease treatments for end-stage renal disease patients, primarily through outpatient centers, value-based care models, and care enablement services targeting nephrologists and healthcare providers in North America, Europe, Asia-Pacific, and Latin America. In recent developments, Fresenius Medical Care advances its FME Reignite strategy by investing EUR 312 million in September 2025 to increase ownership in Interwell Health, a renal value-based care leader, accelerating vertical integration following the 2022 merger of Cricket Health, Interwell Health, and Fresenius Health Partners; it divests select kidney disease laboratory testing assets of Spectra Laboratories to Quest Diagnostics in early 2025 to enhance operational efficiencies; and launches the FME Reignite strategy in June 2025 to strengthen core operations, drive innovation, and improve cash flow with planned annual capex of EUR 800 million to EUR 1 billion through 2030.
Fresenius Medical Care AG & Co. KGaA Q2 Earnings Call Highlights
FMS Q2 Earnings Rise on Care Delivery, Revenues Miss, Margins Expand
Silicon Motion Showcases Next-Generation Storage Solutions for Agentic AI Applications at FMS 2026
Silicon Motion Showcases Next-Generation Storage Solutions for Agentic AI Applications at FMS 2026
Fresenius Medical Care AG (FMS) Q2 2026 Earnings Call Transcript
Fresenius Medical Care AG & Co. KGaA Q2 Earnings Call Highlights
Fresenius Medical Care Shares Drop After U.S. Treatment Volumes Fall Further
Kioxia Showcases Flash Storage Innovations for the AI Era at FMS 2026
Dialysis firm FMC's shares slide despite earnings beat as US volumes disappoint again
Fresenius Medical Care beats quarterly profit estimates, sticks to 2026 outlook
Silicon Motion Showcases Next-Generation Storage Solutions for Agentic AI Applications at FMS 2026
Marvell to Showcase Advanced AI Memory and Storage Infrastructure Portfolio for Agentic AI Inference at FMS 2026
Hikma and Fresenius best positioned from Trump's generic drug tariffs, says Citi
Ryder Reports Second Quarter 2026 Results
Fresenius Medical Care: More Favorable Patient Outcomes Will Drive Growth
Fresenius Medical: High Yield, Utilities-Like Stock At Valuation Lows
Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now
DVA vs. FMS: Which Dialysis Leader Is Better Positioned Now?
Focus Graphite Announces SEDAR+ Filing of the NI 43-101 Technical Report with the Updated Mineral Resource for the Lac Tetepisca Project
Focus Graphite Completes Final Major ESIA Technical Study, Advancing Lac Knife Toward Permitting